- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- January 2019
- 30 Pages
China
From €2002EUR$2,200USD£1,716GBP
- Report
- January 2024
- 143 Pages
Global
From €3868EUR$4,250USD£3,316GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1138EUR$1,250USD£975GBP
- Report
- August 2024
- 80 Pages
Japan
From €3185EUR$3,500USD£2,731GBP
- Report
- February 2024
- 110 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- October 2024
- 86 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- July 2024
- 280 Pages
Global
From €2416EUR$2,655USD£2,071GBP
The Luteinizing Hormone (LH) market is a subset of the Sexual and Reproductive Health Drugs market. LH is a hormone produced by the pituitary gland that plays a key role in the reproductive system. It is responsible for stimulating the production of testosterone in men and the production of estrogen in women. LH is also responsible for triggering ovulation in women and the production of sperm in men. LH is used in the treatment of infertility, polycystic ovary syndrome, and other reproductive disorders. LH is also used in the diagnosis of certain reproductive disorders, such as hypogonadism and pituitary tumors.
The LH market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Merck, Pfizer, Novartis, Sanofi, and Bayer. Other companies in the market include AbbVie, AstraZeneca, and Eli Lilly. Show Less Read more
